Last reviewed · How we verify
Alemtuzumab i.v.
CD52 is a surface protein on mature lymphocytes; Alemtuzumab binds to CD52 and induces cell death.
CD52 is a surface protein on mature lymphocytes; Alemtuzumab binds to CD52 and induces cell death. Used for Chronic lymphocytic leukemia.
At a glance
| Generic name | Alemtuzumab i.v. |
|---|---|
| Sponsor | German CLL Study Group |
| Drug class | Monoclonal antibody |
| Target | CD52 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Alemtuzumab is a monoclonal antibody that targets CD52, a protein found on mature lymphocytes. By binding to CD52, Alemtuzumab induces cell death, leading to the depletion of lymphocytes.
Approved indications
- Chronic lymphocytic leukemia
Common side effects
- Infusion-related reactions
- Infections
- Cytopenias
Key clinical trials
- Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) (PHASE1, PHASE2)
- Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) (PHASE2)
- Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD (PHASE3)
- Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia (PHASE1, PHASE2)
- Alemtuzumab and CHOP in T-cell Lymphoma (PHASE3)
- Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders (PHASE2)
- Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL) (PHASE2)
- A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alemtuzumab i.v. CI brief — competitive landscape report
- Alemtuzumab i.v. updates RSS · CI watch RSS
- German CLL Study Group portfolio CI